Biopharma Datebook: What’s On The Agenda This Week
This article was originally published in The Pink Sheet Daily
Events on tap include release of GWU’s obesity drugs outcomes report, developed at FDA’s request, and the sure-to-be contentious Forest shareholders meeting.
You may also be interested in...
A brief mention in an SEC filing revealed that Merck has ceased the development of a combination cholesterol pill; the once hot ‘0524 program had languished in late-stages for several years.
During its second quarter earnings call, the biotech said it sees recent FDA approvals of two other obesity drugs as a positive for its own prospects, but it is re-engaging with the agency on why it must perform a cardiovascular-outcomes trial prior to approval.
One exception to the slow-growth outlook is the surprise success of Bystolic (nebivolol), the 16th beta blocker to enter the heavily generalized market, but a product the firm has been able to differentiate more by its tolerability than its efficacy.